Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 185Neoplasms 181Carcinoma, Non-Small-Cell Lung 153Prostatic Neoplasms 120Colorectal Neoplasms 111Lung Neoplasms 97Ovarian Neoplasms 83Neoplasm Metastasis 82Multiple Myeloma 76Pancreatic Neoplasms 75Leukemia, Myeloid, Acute 65Endometrial Neoplasms 52Stomach Neoplasms 48Squamous Cell Carcinoma of Head and Neck 47Melanoma 47Recurrence 46Lymphoma 45Hematologic Neoplasms 44Glioblastoma 44Carcinoma, Renal Cell 44Brain Neoplasms 44Carcinoma, Hepatocellular 42Urinary Bladder Neoplasms 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Lymphoma, Non-Hodgkin 39Leukemia, Lymphocytic, Chronic, B-Cell 38Triple Negative Breast Neoplasms 35Glioma 35Small Cell Lung Carcinoma 34Sarcoma 34

Interventions

Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Amyotrophic Lateral Sclerosis × 30 days × Clear all
NCT07002034 2026-06-03

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Reunion Neuroscience Inc

Phase 2 Recruiting
100 enrolled

Adjustment Disorders, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Depression, Multiple Sclerosis, Neoplasms, Idiopathic Pulmonary Fibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡